Abstracts tagged "Psoriatic arthritis"

Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef Smolen¹, Peter Nash ², Hasan Tahir ³, Hendrik Schulze-Koops ⁴, Lingnan Li ⁵, Maja Hojnik ⁶, Amanda Gellett ⁵, Soyi Liu-Leage ⁷, Sreekumar Pillai ⁷ and Philip J. Mease ⁸, ¹Medical University of Vienna, Vienna, Austria, ²Griffith University, Brisbane, Queensland, Australia, ³Royal Free London NHS Trust, London, United Kingdom, ⁴Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Eli Lilly and Company, Indianapolis, Indiana, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Swedish Medical Center and University of Washington, Seattle, Washington
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
Abstract Number: 425 • 2019 ACR/ARP Annual Meeting
Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN
Jörg Wendler ¹, Peter Wagener ², Schwarze Ilka ³, Evgenia Movshovich⁴, Nils Damann ⁴ and Frank Behrens ⁵, ¹Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ²Fachpraxis für Rheumatologie und Osteologie, Bruchhausen-Vilsen, Germany, ³Praxis für Innere Medizin und Rheumatologie, Leipzig, Germany, ⁴Janssen-Cilag, Neuss, Germany, ⁵Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany
Background/Purpose: The wish of a treating physician is to make sure, that the patient gets an effective and safe therapy and is satisfied with the…
Abstract Number: 1079 • 2019 ACR/ARP Annual Meeting
Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018
M. Elaine Husni ¹, Brian Ung², Sven Richter ², Corey Pelletier ² and Marc Tian ², ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Celgene Corporation, Summit
Background/Purpose: Many new PsA treatments have emerged without clear guidelines on which therapy to use initially. We describe PsA treatment trends and patient journeys between…
Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
Abstract Number: 1524 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
Alice Gottlieb ¹, Ana-Maria Orbai ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Luis R. Espinoza ⁵, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved by the FDA to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo-controlled, phase 2b…
Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Rohan Machhar¹, Justine (Yang) Ye ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
Abstract Number: 2451 • 2019 ACR/ARP Annual Meeting
Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Rebecca Persson¹, Katrina Wilcox Hagberg ¹, Ellen Qian ¹, Catherine Vasilakis-Scaramozza ¹, Steve Niemcryk ², Michael Peng ², Maria Paris ², Anders Lindholm ² and Susan Jick ³, ¹Boston Collaborative Drug Surveillance Program, Lexington, ²Celgene Corporation, Summit, ³Boston Collaborative Drug Surveillance Program and Boston University School of Public Health, Boston
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for cardiovascular (CV) events, but different treatment options may not have the same rates of…
Abstract Number: 2472 • 2019 ACR/ARP Annual Meeting
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia – Interim Analysis
Ari Polachek¹, Victoria Furer ², Mirna Zureik ², Sharon Nevo ², Liran Mendel ², David Levartovsky ³, Jonathan Wollman ⁴, Valerie Aloush ⁵, Mark Berman ⁶, Ilana Kaufman ⁶, Yael Lahat ², Hagit Sarbagil-Maman ⁷, Sara Borok ⁶, Adi Broyde ⁶, Lihi Eder ⁸, Daphna Paran ¹ and Ori Elkayam ⁹, ¹Tel-Aviv Sourasky medical center, Tel Aviv, Israel, ²Sourasky Medical Center, Tel-Aviv, Israel, ³Sourasky medical center, Tel Aviv, Israel, ⁴Sourasky Medical Center, Herzelia, Israel, ⁵Tel Aviv Sourasky medical center, Tel Aviv, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Tel-Aviv Sourasky medical center, Qiryat-Ono, Israel, ⁸Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁹Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis is a chronic inflammatory disease. More than 20% of patients with PsA patients suffer from fibromyalgia, a chronic pain syndrome characterized by…
Abstract Number: 2492 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review
Andreas Kerschbaumer¹, Josef Smolen ¹, Maxime Dougados ², Maarten de Wit ³, Jette Primdahl ⁴, Iain McInnes ⁵, Désirée van der Heijde ⁶, Louise Falzon ⁷, Xenofon Baraliakos ⁸ and Laure Gossec ⁹, ¹Medical University of Vienna, Vienna, Austria, ²Cochin Hospital, Paris, France, ³Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁴Dansk Gigthospital, Sønderborg, Denmark, ⁵Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Northwell Health, New York, ⁸Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: There is now an increasing range of drug options in PsA. To inform the update of the EULAR PsA management recommendations (Ref 1), we…
Abstract Number: 2713 • 2019 ACR/ARP Annual Meeting
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Dax Rumsey¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Laura Schanberg ⁴, Jennifer Schenfeld ⁵, Natalie Shiff ⁶, Matthew Stoll ⁷, Scott Stryker ³, Pamela F. Weiss ⁸ and Timothy Beukelman ⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Duke University, Durham, NC, ³Amgen Inc., Thousand Oaks, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Amgen, Inc, Thousand Oaks, CA, ⁶University of Florida, Gainesville, FL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Herein we describe characteristics of children with juvenile spondyloarthritis (JSpA, i.e. enthesitis-related arthritis [ERA] or juvenile psoriatic arthritis [JPsA]) enrolled in the Childhood Arthritis…
Abstract Number: 426 • 2019 ACR/ARP Annual Meeting
Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
Dafna Gladman¹, Laura Coates ², Joseph Wu ³, Lara Fallon ⁴, Ming-Ann Hsu ⁵, Andrew Bushmakin ³, Elizabeth Bacci ⁶, Joseph Cappelleri ³ and Philip Helliwell ⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Montreal, QC, Canada, ⁵Pfizer Inc, Collegeville, PA, ⁶Evidera, Seattle, WA, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: With many disease domains affected in PsA, clinical and patient-reported outcome (PRO) measures are important to assess disease improvement following treatment. Rapid, meaningful improvements…
Abstract Number: 1081 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Angel Cronin ², Blessing Dube ², Robert McLean ², Esther Yi ³, Peter Hur ³ and Philip Mease ⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients…
Abstract Number: 1479 • 2019 ACR/ARP Annual Meeting
Multi-Symptom Impact on the EQ5D Index in Bio-naïve Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study
Alexis Ogdie¹, Nan Li ², Steve Peterson ², Chetan Karyekar ², Soumya Chakravarty ³, Shelly Kafka ⁴ and Jessica Walsh ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis and skin and nail psoriasis. The impact of…
Abstract Number: 1525 • 2019 ACR/ARP Annual Meeting
Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Christopher Ritchlin ¹, Vibeke Strand ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Arthur Kavanaugh ⁵, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tildrakizumab (TIL) is an anti–interleukin-23p19 monoclonal antibody approved by the FDA for treatment of moderate-to-severe plaque psoriasis1,2 and is under investigation for treatment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].